A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE) - ACE study

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Subject is at least 18 and no older than 75 years of age
•Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
•Subject has an indication for treatment with CE regimen
•Subject is expected to receive at least 2 cycles of CE regimen
•Subject is able to swallow capsules

•Documented history of sensitivity/idiosyncrasy to aprepitant capsules or exipients
•Relevant history or current condition that might interfere with drug absorption
•History or current abuse of drugs, alcohol or solvents
•Inability to understand the nature and extent of the trial and the procedures required
•Participation in a drug trial within 30 days before the first dose
•Febrile illness within 3 days before the first dose
•Concomitant use of agents that are known to interfere with aprepitant pharmacokinetics
•Abnormal liver or renal function

发起方

niversitair Medisch Centrum Sint Radboud